Study Information

Respiratory Syncytial Virus causes upper and lower respiratory tract illness. Upper respiratory symptoms typically begin within several days of RSV infection. Often, the infection remains in the upper respiratory tract. However, in infants and young children, individuals with weakened immune systems, and older adults, the virus may descend to the lower respiratory tract, leading to wheezing, bronchiolitis and potentially hospitalization, ventilation, and in rare cases even death. Infections with RSV follow a seasonal pattern, mostly occurring in Australia between the months of March and October.

To date no effective vaccine to prevent RSV has been licensed, and treatment is limited to supportive therapy. This study is looking at a potential new vaccine, it is designed to prevent acute RSV associated respiratory illness and lower respiratory tract infections (LRTI) caused by RSV. It is based on a new process, which allows for a much quicker production of the vaccine.


If you are interested in participating, please register below.

  • 9
    Outpatient Visits

Minimum Eligibility Requirements:

  • Healthy males or healthy females who are surgically sterile or post-menopausal (physically cannot have any more children)
  • Aged 18 - 49 years old OR aged 60 - 79 years old
  • BMI 18.0 – 32 kg/m²
  • Non-smokers for the last 4 weeks